TheEdgeResearch
Home / Stocks / AVTX

Avalo Therapeutics, Inc. (AVTX)

NASDAQ Healthcare Biotechnology
$15.47 ▼ -1.59%
Market Cap
$813.2M
Sector
Healthcare
Industry
Biotechnology
Beta
0.79
52-Wk Range
12.409-24.27
CEO
Garry A. Neil
Country
US
Currency
USD

Avalo Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wayne, PA, US. The stock last traded at $15.47, down 1.59% on the session, giving a market capitalisation of $813.2M. On trailing twelve-month figures it carries a trailing P/E of -3.26, a net margin of -170055.9%. Its beta of 0.79 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-3.26
Price / Sales
13782.88
Price / Book
1.50
EV / EBITDA
-7.28
Gross margin
-16861.0%
Operating margin
-154844.1%
Net margin
-170055.9%
Return on equity
—
Debt / equity
0.00
Current ratio
19.31
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
33
IPO date
2015-10-14
Headquarters
Wayne, PA, US
About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.

Comparable companies

Avalo Therapeutics, Inc. is most often compared with the following Healthcare names:

AARDBDTXCHRSCRBUENTAEPRXIVAOBIOPRLDTNYA
More research on AVTX
AVTX technical analysis AVTX TheEdge Score Compare against peers
Open full interactive analysis & DCF →